^
Association details:
| Biomarker: | IDH1 R132C + PIK3CA E545K + IDH2 R172K |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Tibsovo (ivosidenib) (IDH1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
Published date:
09/02/2022
Excerpt:
He was treated with ivosidenib 500 mg daily, which he tolerated well with prolonged stable disease (Fig. 1b). After 17 months of ivosidenib treatment, he developed progressive disease in his liver and was taken off the trial. CfDNA analysis performed at the time of disease progression demonstrated persistence of IDH1 R132C (MAF, 2.1%) and PIK3CA E545K (MAF, 2.2%) and acquisition of a new IDH2 R172K mutation (MAF, 0.7%)...
DOI:
https://doi.org/10.1038/s41698-022-00304-5
